Study to Assess Monoclonal B-Cell Lymphocytosis in Individuals With Chronic Hepatitis C

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

29 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-14

Study Completion Date

2025-12-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the incidence of monoclonal B-cell lymphocytosis MBL) in patients with chronic hepatitis C and to determine if monoclonal b-cell lymphocytosis is affected by treatment for hepatitis C.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C

NCT00952263

Healthy

COMPLETED PHASE1

Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin

NCT00230854

Chronic Hepatitis C Hepatitis, Viral, Human

COMPLETED PHASE1

Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C

NCT01121185

HCV Infection Liver Transplantation

TERMINATED PHASE2

Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

NCT02836925

Indolent B-cell Lymphoma Hepatitis C

COMPLETED PHASE2

Factors Associated to Success of Hepatitis C Therapy

NCT00514111

Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the prevalence of MBL in patients with chronic hepatitis C who are to begin therapy with directly acting antiviral (DAA), and compare with clinic controls who are seen in the general medicine clinic at Mayo Clinic.

II. To determine the correlation between the specific subtype of MBL (CD5- MBL, atypical CLL-phenotype MBL and CLL-phenotype MBL) relative to the hepatitis C virus (HCV) genotype.

III. To assess the proportion of individuals with MBL who have an improvement in the circulating monoclonal B-cell population following therapy with DAA.

OUTLINE: This is an observational study.

Patients undergo blood sample collection and have medical records reviewed throughout study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Viral Hepatitis C Monoclonal B-Cell Lymphocytosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational

Patients undergo blood sample collection and have medical records reviewed throughout study.

Non-Interventional Study

Intervention Type OTHER

Non-interventional study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-Interventional Study

Non-interventional study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals with chronic hepatitis C who are to begin therapy with DAA

* Willing to submit a peripheral blood sample at baseline, end of therapy, 12 weeks after the end of therapy, and 52 weeks from baseline

Exclusion Criteria

* Individuals with chronic hepatitis C who have cirrhosis

* Individuals with chronic hepatitis C who have a past history of a lymphoproliferative disorder AND for which they received chemotherapy

Eligible Sex

ALL

Accepts Healthy Volunteers

No